Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies

Vibeke Strand; Peter E. Lipsky; Grant W. Cannon; Leonard H. Calabrese; Craig Wiesenhutter; Stanley B. Cohen; Nancy J. Olsen; Martin L. Lee; Todd J. Lorenz; Betty Nelson; Frederick Wolfe; Roy M. Fleischmann; Reynold M. Karr; George H. Krick; Thomas A. Medsger; William F.C. Rigby; David A. Fox; Timothy J. Swartz; Carter V. Multz; Michael H. Weisman

doi:10.1002/art.1780360508

Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies

Vibeke Strand, Peter E. Lipsky, Grant W. Cannon, Leonard H. Calabrese, Craig Wiesenhutter, Stanley B. Cohen, Nancy J. Olsen, Martin L. Lee, Todd J. Lorenz, Betty Nelson, Frederick Wolfe, Roy M. Fleischmann, Reynold M. Karr, George H. Krick, Thomas A. Medsger, William F.C. Rigby, David A. Fox, Timothy J. Swartz, Carter V. Multz, Michael H. Weisman

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Abstract

Objective. To evaluate the safety and activity of an immunoconjugate of ricin A chain and anti‐CD5 monoclonal antibody (anti‐CD5 IC), with and without concomitant methotrexate and/or azathioprine, in the treatment of rheumatoid arthritis (RA). Methods. Seventy‐nine patients with active RA were enrolled in 2 prospective open‐label protocols. Results. Using composite criteria, response rates were 50–68% at 1 month and 22–25% at 6 months. Transient depletion of CD3/CD5 T cells was observed on days 2 and 5 of treatment, with reconstitution on day 15 or day 29. Treatment‐associated adverse effects were common but resolved rapidly without sequelae. Conclusion. These findings suggest activity of anti‐CD5 IC in active RA and warrant confirmation in a multicenter randomized study (currently underway).

Original language	English (US)
Pages (from-to)	620-630
Number of pages	11
Journal	Arthritis & Rheumatism
Volume	36
Issue number	5
DOIs	https://doi.org/10.1002/art.1780360508
State	Published - May 1993

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Rheumatology
Immunology
Pharmacology (medical)

Access to Document

10.1002/art.1780360508

Cite this

Strand, V., Lipsky, P. E., Cannon, G. W., Calabrese, L. H., Wiesenhutter, C., Cohen, S. B., Olsen, N. J., Lee, M. L., Lorenz, T. J., Nelson, B., Wolfe, F., Fleischmann, R. M., Karr, R. M., Krick, G. H., Medsger, T. A., Rigby, W. F. C., Fox, D. A., Swartz, T. J., Multz, C. V., & Weisman, M. H. (1993). Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies. Arthritis & Rheumatism, 36(5), 620-630. https://doi.org/10.1002/art.1780360508

@article{d6f9c23c57b3460a9272dad2dd454396,

title = "Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies",

abstract = "Objective. To evaluate the safety and activity of an immunoconjugate of ricin A chain and anti‐CD5 monoclonal antibody (anti‐CD5 IC), with and without concomitant methotrexate and/or azathioprine, in the treatment of rheumatoid arthritis (RA). Methods. Seventy‐nine patients with active RA were enrolled in 2 prospective open‐label protocols. Results. Using composite criteria, response rates were 50–68% at 1 month and 22–25% at 6 months. Transient depletion of CD3/CD5 T cells was observed on days 2 and 5 of treatment, with reconstitution on day 15 or day 29. Treatment‐associated adverse effects were common but resolved rapidly without sequelae. Conclusion. These findings suggest activity of anti‐CD5 IC in active RA and warrant confirmation in a multicenter randomized study (currently underway).",

author = "Vibeke Strand and Lipsky, {Peter E.} and Cannon, {Grant W.} and Calabrese, {Leonard H.} and Craig Wiesenhutter and Cohen, {Stanley B.} and Olsen, {Nancy J.} and Lee, {Martin L.} and Lorenz, {Todd J.} and Betty Nelson and Frederick Wolfe and Fleischmann, {Roy M.} and Karr, {Reynold M.} and Krick, {George H.} and Medsger, {Thomas A.} and Rigby, {William F.C.} and Fox, {David A.} and Swartz, {Timothy J.} and Multz, {Carter V.} and Weisman, {Michael H.}",

year = "1993",

month = may,

doi = "10.1002/art.1780360508",

language = "English (US)",

volume = "36",

pages = "620--630",

journal = "Arthritis & Rheumatism",

issn = "0004-3591",

publisher = "John Wiley and Sons Ltd",

number = "5",

}

Strand, V, Lipsky, PE, Cannon, GW, Calabrese, LH, Wiesenhutter, C, Cohen, SB, Olsen, NJ, Lee, ML, Lorenz, TJ, Nelson, B, Wolfe, F, Fleischmann, RM, Karr, RM, Krick, GH, Medsger, TA, Rigby, WFC, Fox, DA, Swartz, TJ, Multz, CV & Weisman, MH 1993, 'Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies', Arthritis & Rheumatism, vol. 36, no. 5, pp. 620-630. https://doi.org/10.1002/art.1780360508

TY - JOUR

T1 - Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies

AU - Strand, Vibeke

AU - Lipsky, Peter E.

AU - Cannon, Grant W.

AU - Calabrese, Leonard H.

AU - Wiesenhutter, Craig

AU - Cohen, Stanley B.

AU - Olsen, Nancy J.

AU - Lee, Martin L.

AU - Lorenz, Todd J.

AU - Nelson, Betty

AU - Wolfe, Frederick

AU - Fleischmann, Roy M.

AU - Karr, Reynold M.

AU - Krick, George H.

AU - Medsger, Thomas A.

AU - Rigby, William F.C.

AU - Fox, David A.

AU - Swartz, Timothy J.

AU - Multz, Carter V.

AU - Weisman, Michael H.

PY - 1993/5

Y1 - 1993/5

N2 - Objective. To evaluate the safety and activity of an immunoconjugate of ricin A chain and anti‐CD5 monoclonal antibody (anti‐CD5 IC), with and without concomitant methotrexate and/or azathioprine, in the treatment of rheumatoid arthritis (RA). Methods. Seventy‐nine patients with active RA were enrolled in 2 prospective open‐label protocols. Results. Using composite criteria, response rates were 50–68% at 1 month and 22–25% at 6 months. Transient depletion of CD3/CD5 T cells was observed on days 2 and 5 of treatment, with reconstitution on day 15 or day 29. Treatment‐associated adverse effects were common but resolved rapidly without sequelae. Conclusion. These findings suggest activity of anti‐CD5 IC in active RA and warrant confirmation in a multicenter randomized study (currently underway).

AB - Objective. To evaluate the safety and activity of an immunoconjugate of ricin A chain and anti‐CD5 monoclonal antibody (anti‐CD5 IC), with and without concomitant methotrexate and/or azathioprine, in the treatment of rheumatoid arthritis (RA). Methods. Seventy‐nine patients with active RA were enrolled in 2 prospective open‐label protocols. Results. Using composite criteria, response rates were 50–68% at 1 month and 22–25% at 6 months. Transient depletion of CD3/CD5 T cells was observed on days 2 and 5 of treatment, with reconstitution on day 15 or day 29. Treatment‐associated adverse effects were common but resolved rapidly without sequelae. Conclusion. These findings suggest activity of anti‐CD5 IC in active RA and warrant confirmation in a multicenter randomized study (currently underway).

UR - http://www.scopus.com/inward/record.url?scp=0027299097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027299097&partnerID=8YFLogxK

U2 - 10.1002/art.1780360508

DO - 10.1002/art.1780360508

M3 - Article

C2 - 7683881

AN - SCOPUS:0027299097

SN - 0004-3591

VL - 36

SP - 620

EP - 630

JO - Arthritis & Rheumatism

JF - Arthritis & Rheumatism

IS - 5

ER -

Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this